To include your compound in the COVID-19 Resource Center, submit it here.

FDA issues final guidance for antibacterial streamlined program

FDA issued final guidance for companies developing new antibacterial drugs. The guidance outlines a streamlined development program for products targeting serious bacterial diseases in patients with an unmet medical need, including

Read the full 311 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE